Skip to Content

Case Overview

Status:Status:Investigating
Company Name:Company Name:EyePoint Pharmaceuticals
Ticker:Ticker:EYPT
Related Attorneys:Lead Attorneys:Thomas W. Elrod
Related Practices:Related Practices:Securities
On August 14, 2026, EyePoint released topline results in its Phase 3 LUGANO wet AMD trial for DURAVYU, revealing that DURAVYU missed the prespecified primary endpoint—change in best-corrected visual acuity versus on-label aflibercept. Previously, on March 25, 2026, President and CEO Jay S. Duker had stated they were “highly confident in the results of these trials [including Phase 3 LUGANO] at this point for a lot of reasons.” On June 9, he reiterated that they “remain quite confident and quite optimistic in the results and we think we can make a difference for patients.” On this news, the Company’s stock price declined $9.88, or 67%, to close at $4.87 on August 17, 2026.
 

Contact Us About This Case

You may share a link to this page on any of the sites listed below or send link via email: